Quantcast

Latest bladder cancer Stories

2014-06-17 08:29:08

SAN DIEGO, June 17, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced that mocetinostat, the company's spectrum selective HDAC inhibitor, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration as a treatment for myelodysplastic syndrome (MDS). Mocetinostat is being developed in Phase 2 clinical studies in combination with Vidaza as a treatment for intermediate and high-risk MDS, as well as a single agent treatment in patients with...

2014-06-03 12:15:53

Yale University A multi-center phase I study using an investigational drug for advanced bladder cancer patients who did not respond to other treatments has shown promising results in patients with certain tumor types, researchers report. Yale Cancer Center played a key role in the study, the results of which will be presented Saturday, May 31 at the 2014 annual conference of the American Society of Clinical Oncology (ASCO) in Chicago. The trial included 68 people with previously...

2014-06-01 23:01:25

The Firm is investigating Actos lawsuits on behalf of Type 2 diabetes patients who allegedly developed bladder cancer due to their use of the medication. New York, New York (PRWEB) June 01, 2014 Thousands of Actos lawsuits (http://www.theactoslawsuitcenter.com/) that allege the use of the Type 2 diabetes medication can increase the risk that a patient will develop bladder cancer continue to move forward in a multidistrict litigation underway in U.S. District Court, Western District of...

2014-05-28 08:32:22

DUNEDIN, New Zealand and HERSHEY, Pa., May 28, 2014 /PRNewswire/ -- Pacific Edge announced today that it has entered into a contractual agreement with MultiPlan, Inc. for diagnostic laboratory testing. The agreement includes Pacific Edge's participation in the MultiPlan, PHCS and PHCS Savility Networks. http://photos.prnewswire.com/prnvar/20131015/MM98246LOGO The agreement is the fourth signed with national provider networks by Pacific Edge since October 2013 and is another step in...

2014-05-20 08:34:22

AADi Initiates NIH Funded Clinical Trial for Patients with Bladder Cancer PACIFIC PALISADES, Calif., May 20, 2014 /PRNewswire/ -- AADi, LLC, a clinical stage biopharmaceutical company focused on treating diseases uniquely suited for nanotechnology approaches, today announced the inlicensing of ABI-009 from Celgene Corporation (NASDAQ:CELG). ABI-009 is the nanoparticle albumin-bound (nab®) version of the mTOR inhibitor sirolimus or rapamycin and leverages the same technology of the...

2014-05-17 12:20:25

Studies discuss physical activity, obesity, and hematuria evaluation across race and gender in bladder cancer mortality risk ORLANDO, Fla., May 17, 2014 /PRNewswire-USNewswire/ -- Aside from all the benefits exercise and physical activity have on our bodies and health, a new study reveals those who take part in physical activity and exercise can add lowering their risk of dying from bladder cancer to the list. Even light to moderate exercise can make a difference. In a separate study, data...

2014-05-15 23:15:29

The alleged link between Takeda’s Actos diabetes drug and bladder cancer continues to hear arguments in the nation’s courts amidst a backdrop of sanctions and chastisements over destroyed documents and misconduct. LawyersandSettlements.com provides an update on Actos lawsuit progress. Las Vegas, NV (PRWEB) May 15, 2014 Amidst a backdrop of court records showing jury awards for plaintiffs in previous Actos cases that were later vacated*, and censure by the court over destroyed...

2014-05-11 23:01:10

The Firm is evaluating Actos lawsuits on behalf of patients who allegedly developed bladder cancer due to long-term use of the Type 2 diabetes drug. New York, New York (PRWEB) May 11, 2014 Thousands of Actos lawsuits (http://www.theactoslawsuitcenter.com/) that allege long-term use of the Type 2 diabetes drug caused patients to develop bladder cancer continue to move forward in a federal multidistrict litigation underway in U.S. District Court, Western District of Louisiana, Bernstein...

2014-05-06 23:14:36

Flood Law Group continues to investigate potential Actos lawsuits on behalf of patients who developed bladder cancer after taking Actos in light of the recent developments in Actos litigation. Washington, D.C. (PRWEB) May 06, 2014 District Judge Kerry Early said she found the lawyers for Takeda Pharmaceuticals to be disrespectful during an Actos trial in Las Vegas. As a result, she said she has agreed to impose monetary sanctions for any additional violations of her orders. (Case Nos....

2014-05-06 16:29:13

LONDON, May 6, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapieshttp://www.reportbuyer.com/pharma_healthcare/diseases/solid_tumors_market_asia_pacific_2019_new_drug_approvals_anticipated_product_launches_trigger_shift_treatment_paradigm_targeted_therapies.htmlSolid Tumors Market in Asia Pacific to...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related